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ABSTRACT 
 
Paget’s disease of bone (PDB) is a focal bone disorder affecting the skeleton segmentally. A strong 
genetic component has been shown in PDB, and variants in several genes, as SQSTM1, VCP, and 
OPTN, have been associated with the disease. Mutations in the same genes have also been reported in 
patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). 
Hexanucleotide repeat expansions in the C9ORF72 gene have been shown to be responsible for both 
familial and sporadic FTD/ALS. Thence, we evaluated the frequency of the C9ORF72 
hexanucleotide repeat expansions in a cohort of 191 Italian PDB patients and in 106 controls. The 
pathogenic repeat expansion was detected in 2 PDB patients (1.0%). During the follow-up period, 
both PDB patients did not develop any sign of mental decline and/or motor neuron disease. Our study 
suggests that repeat expansions in the C9ORF72 gene are rare in patients with Paget’s disease of 
bone.  
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Introduction 
Paget’s disease of bone (PDB) (OMIM 602080) is the second most common skeletal disorder after 
osteoporosis. PDB generally affects approximately 1% of adults in Western Europe, increasing 
significantly with age to affect about 5% of people aged 85 years. The disease is characterized by 
focal areas of abnormal bone metabolism, due to increased activity of both osteoclasts and 
osteoblasts, resulting in formation of disorganized bone (Galson et al., 2014). Additional 
abnormalities include bone marrow fibrosis and increased vascularity of affected bones. The most 
commonly affected bones are the pelvis, the spine, the femora and the skull but any bone of the 
skeleton may be affected. Thence, the disease may be diagnosed incidentally by skeletal radiographs 
or by biochemical finding of an unexplained elevation of serum alkaline phosphatase. About one 
third of PDB patients have only one affected bone and are asymptomatic. The commonest symptoms 
are pain, due to pagetic lesions in bone itself or caused by pathological fractures, bone enlargement, 
deformity, and deafness. 
 
The etiology of PDB has remained largely unknown for several decades. Recent studies suggested 
that the disease is due to a complex interaction between several genetic and environmental risk 
factors. Epidemiologic studies have indicated a strong genetic component in PDB: 15 to 40% of 
patients have a familial form of the disease, which is transmitted in an autosomal-dominant model of 
inheritance with incomplete penetrance (Ralston et al., 2014). To date, causative PDB mutations have 
been identified mainly in the SQSTM1 gene, coding for the p62 protein, with a frequency of 25–50% 
in familial and 5–10% in sporadic patients (Laurin et al., 2002).  In addition, mutations in the VCP 
gene have been associated with a complex phenotype that comprises inclusion body myopathy, 
Paget's disease of bone and Frontotemporal dementia (IBMPFD) (Weihl et al., 2009). Finally, genetic 
variants in several genes, including CSF1, TNFRSF11A, TNFRSF11B, and OPTN, have also been 
implicated in the pathogenesis of the disease. 
 
In the last few years, mutations in some of the genes involved in PDB have also been described in 
patients with frontotemporal dementia (FTD) and/or amyotrophic lateral sclerosis (ALS), suggesting 
the presence of overlapping pathogenetic mechanisms. SQSTM1 gene mutations have been found in 
approximately 2.5% of patients with ALS and 3% of patients with FTD (Rainero et al., 2017). An 
UK kindred segregating the P392L mutation in the SQSTM1 gene showed the coexistence of both 
ALS and PDB phenotypes (Kwok et al., 2014). Finally, mutations in the OPTN gene were also 
recently reported in patients with ALS. Taken together, these data suggest that genes involved in the 
ALS/FTD spectrum might be investigated as candidate genes also in PDB patients (Rea et al., 2014). 
 
Few years ago, a pathogenic expansion of hexanucleotide repeats in the C9ORF72 gene was 
identified as a major cause of familial FTD and ALS (DeJesus-Hernandez et al., 2011; Renton et al., 
2011). The mechanisms through which the C9ORF72 expansion contributes to these disorders 
include both loss and gain-of-function mechanisms, driven by toxic RNA. These mechanisms have 
been linked to both defective nucleocytoplasmic trafficking and nuclear stress (Zhang et al., 2016). 
Interestingly, in a family with FTD and concomitant PDB, the co-occurrence of the P392L mutation 
in SQSTM1 and the C9ORF72 pathological expansions was recently reported (Almeida et al., 2016).  
Therefore, the aim of this study was to evaluate the frequency of C9ORF72 expansion in a cohort of 
Italian patients with Paget’s disease of bone and to evaluate the correlation with clinical phenotype.  
 
 
Material and methods 
One hundred ninety one unrelated patients with Paget disease of bone (103 men, 88 women; mean 
age± SD = 68.6± 12.8 years), attending the Unit of Geriatrics and Metabolic Bone Disorders, 
Department of Internal Medicine, University of Torino, were recruited in the study. The diagnosis 
of PDB was made according to the established criteria, based both on alkaline phosphatase levels 
and bone radiologic/scintigraphic examinations. A positive family history, defined as at least one 
first-degree relative having PDB, was recorded in 22% of PDB patients. The age of onset was 64.2± 
9.5 years in the female cohort, and of 59.8± 10.1 in the male subgroup. About 50% patients fulfilled 
the diagnostic criteria for polyostotic disease. Phenotypic data of PDB patients were summarized in 
Table 1. A group of 106 healthy subjects (56 men, 50 women; mean age± SD= 70.9± 9.2 years), 
served as controls. Patients and controls were of Caucasian origin and came from the same area of 
Northern Italy. Written informed consent was obtained from all participants, and the study was 
approved by Hospital Ethics Committee.  
 
The genomic DNA was purified from whole blood leukocytes using a DNA extraction kit (QIAGEN, 
Germany). The presence of a pathological hexanucleotide expansion GGGGCC in the C9ORF72 
gene was evaluated using repeated primed PCR, as previously described (Xi et al., 2014), and a 
characteristic amplification pattern on the electropherogram was considered evidence of a pathogenic 
repeat expansion. Furthermore, PCR reagents were optimized for the amplification of the C9ORF72 
hexanucleotide repeats (AmplideX®PCR/CE C9ORF72 Kit, Asuragen, Inc.). The genomic DNA was 
amplified using a three-primer G4C2-Repeat Primed (RP)-PCR configuration, followed by fragment 
sizing on a 3100 Genetic Analyzer (Thermo Fisher). ROX 1000 was used for sizing by capillary 
electrophoresis and the size of the PCR products were converted to the number of G4C2 repeats 
using size and mobility conversion factor with Gene Mapper v 4.1 software (Thermo Fisher). In 
addition, the presence of mutations in SQSTM1 or in other genes known to be associated with PDB-
related syndromes was investigated. The statistical analyses were performed using SPSS software 
version 21.0. 
 
Results 
The complete analysis of the C9ORF72 gene was conducted on a total of 297 subjects. The 
pathogenic C9ORF72 expansion was detected in two out of 191 patients with Paget’s disease of 
bone, with a frequency of 1.0%. Electropherograms of heterozygous samples with expanded alleles 
were shown in Fig. 1 in the Supplemental Material. No C9ORF72 expansion was observed in the 
control group. The first subject carrying the C9ORF72 expansion did not carry any other mutations in 
known PDB genes, while the second patient also presented the Y383X mutation (c.1149 C>A) in 
exon 7 of SQSTM1 gene.  
 
The two patients had a long-lasting diagnosis of sporadic PDB. The first patient is a male that, at age 
70, developed a polyostotic disorder. Total body bone scintigraphy showed skull, vertebral and pelvic 
involvement. During the clinical follow-up, no clinical signs of motor neuron disease were observed, 
and the patient died at 83 years for myocardial infarction, without showing any sign of mental 
decline.  
The second patient carrying both the C9ORF72 expansion and the mutation in SQSTM1, is a 77-years 
female patient, with an age at onset of PDB at 62 years, who presented with polyostotic disorder (left 
scapula and pelvis). In 2008, the patient has been treated with 5-mg dose of intravenous zoledronate 
once a year with a clinical positive response. In 2018, serum bone alkaline phosphatase was 5.1 
mcg/l, parathyroid hormone was 77 pg/ml, and urinary calcium was in normal range. A positive 
family history for Alzheimer’s disease was reported, with a deceased brother with an age at onset of 
dementia at 64 years (no genetic investigations are available). At clinical examination, no signs of 
motor neuron disease were detected. Mini Mental State Examination was 28/30, and an extended 
neuropsychological examination did not show any sign of cognitive impairment.  
 
 
Discussion 
In this study we analyzed the presence of C9ORF72 expansions in patients with Paget’s disease of 
bone, and we found pathologic expansions with a frequency of approximately 1% of our dataset of 
PDB patients. Our study does not support a major role for C9ORF72 gene in PDB, but suggests that 
this gene could be involved in the pathogenesis of Paget’s disease of bone. In addition, our study 
confirmed the co-occurrence of SQSTM1 and C9ORF72 gene mutations in a patient with PDB. 
 
This is the first study that investigated the prevalence of C9ORF72 expansions in Paget’s disease of 
bone, and we recognize a few limitations. The major limitation of our study is the low number of 
genotyped patients; therefore, the study could be not sufficiently powered. In addition, we did not 
have the possibility to carry out a Southern blot to quantify the length of the expansion, but we used a 
novel methodology that allowed us to quantify the C9ORF72 expansion in the two PDB patients as 
>145 repeats.  
 
Paget’s disease of bone is characterized by abnormal bone remodeling, leading to osteolytic lesions, 
bone deformities, and pathologic fractures. An initial surge of osteoclastic activity leads to focalized 
resorption of bone, followed shortly thereafter by osteoblast hyperactivity. There are several 
evidences suggesting that the development of PDB may be related to a deregulation of autophagy 
(Shapiro et al., 2014). This process plays an essential role in homeostasis by providing energy and 
recycling cellular components, but also by facilitating lysosomal degradation, and aggregates of 
misfolded proteins. Osteoclasts from PDB patients show both nuclear and cytoplasmic inclusions that 
have been associated with protein aggregates, increasing the evidences of a possible deregulation of 
autophagy in the development of the disease. Both SQSTM1 and VCP are involved in autophagy and 
in forming protein aggregates, indicating that a disturbance of these processes might be a risk factor 
for the pathogenesis of PDB. Recent experimental and clinical studies provided evidence that also the 
C9ORF72 gene plays a critical role in autophagy (Todd et al., 2016). In addition, polymorphisms in 
autophagy genes have been found to be associated with Paget’s disease of bone (Usategui-Martin et 
al., 2015). Intriguingly, in an experimental model, a decreased expression of C9ORF72, through an 
inhibition of autophagy, leads to accumulation of cytoplasmic aggregates of p62/SQSTM1 (Webster 
et al., 2016).  At present, however, no data on the possible role of C9ORF72 gene in bone metabolism 
are available. 
 
In this study, we confirmed that mutations in SQSTM1 gene and C9ORF72 expansions may co-occur 
in patients with PDB, as previously described (Almeida et al., 2016). Therefore, it is possible that 
both genes may converge into a common pathogenetic mechanism. Mutations in the SQSTM1 gene 
combined with a C9ORF72 expansion could act in an additive manner to predict the extent and 
severity of PDB. However, owing to the limited number of double mutation carriers described, we 
cannot establish if the co-occurrence of mutations influences the clinical expression of PDB. 
Moreover, age at onset was not clearly different from patients carrying only one of the mutations. 
Finally, we did not find any C9ORF72 expansion in our control group. In literature, in an extensive 
study investigating C9ORF72 expansions in several neurodegenerative diseases, the authors detected 
an expansion of 0.15% in their control population (Beck et al., 2013). However, control samples 
involved in C9ORF72 studies were mainly screened for neurological disorders. It could be of interest 
to review the clinical characteristics of positive C9ORF72 control subjects, in order to exclude also a 
diagnosis of Paget’s disease of bone.   
 
In the present study, we identified a small number of C9ORF72 expansions in a cohort of Italian 
PDB patients. Even if our findings do not support a major role for this gene in PDB pathogenesis, 
additional clinical and experimental studies are warranted to further elucidate the involvement of 
C9ORF72 gene in Paget’s disease of bone. 
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Table 1. Clinical characteristics of patients with Paget’s disease of bone. 
 
 
 
 Males  Females 
Number 103 88 
Age (years ± SD) 66.9 ± 9.9 70.9 ± 9.2 
Age at onset (years ± SD) 59.8 ± 10.1 64.2 ± 9.5 
Familiarity for PDB (%) 18.8% 21.2% 
Patients with polyostotic disease (%) 53.4% 49.4% 
Patients with bone pain (%) 43.9% 63.3% 
Number of bone localizations (mean ± SD) 2.2 ± 2.6 2.3 ± 2.7 
Patients with arthrosis (%) 32.8% 38.6% 
Patients with bone fractures (%) 31.2% 38.6% 
Patients with bone deformations (%) 21.2% 25.6% 
Patients with hearing loss (%) 25.6% 22.6% 
Patients with skull involvement (%) 3.7% 4.2% 
Patients with nephrolithiasis (%) 18.9% 26.3% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highlights 
 
 We evaluated for the first time the frequency of the C9ORF72 hexanucleotide repeat expansions in a 
cohort of Italian PDB patients and in healthy controls. 
 The pathogenic repeat expansion was detected in 2 out of 191 PDB patients (1.0%). One of the two 
patients showed the coexistence of both C9ORF72 expansion and SQSTM1 gene mutation. 
 Our study does not support a major role for C9ORF72 gene in PDB, but suggests that this gene could be 
involved in the pathogenesis of Paget’s disease of bone. 
